human ACE2 – Page 13 – Communicable Diseases Research

Biophysical properties of the isolated spike protein binding helix of human ACE2

인간 ACE2의 분리된 스파이크 단백질 결합 나선의 생물물리학적 특성

Article

Published on 2021-07-202022-09-11
Journal: Biophysical Journal [Category] SARS, 변종, 치료기술,

Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection

인간 ACE2의 돌연변이는 SARS-CoV 및 SARS-CoV-2 스파이크 매개 감염을 차등적으로 촉진합니다

Research Article

Published on 2021-07-162022-09-10
Journal: PLoS Pathogens [Category] SARS, 변종,

[키워드] abrogated abundance ACE2 ACE2 protein ACE2 sequence Affect allele bind binding biochemical Cell cell line cell surface cells change coding coronavirus coronavirus spike proteins correlated CoV spike proteins Cross-species transmission Cytopathic effect cytopathic effects determine Effect Efficiency engage events exomes expressed expression fraction Genetic genomic integration HEK 293T Human human ACE2 human Ace2 protein implication infect cells Infection inhibited Interaction Missense missense mutants Modification mutant mutants N501Y Non-linear relationship nucleotide overlapping parental promote Protein pseudotyped lentivirus pseudovirus entry pseudovirus infection Quantitative receptor protein reduced reducing reference sequence SARS-CoV SARS-CoV entry SARS-CoV-2 SARS-CoV-2 RBD binding SARS-CoV-2 replication SARS-CoV-2 spike SARS-CoV-2 spike proteins SARS-CoV-2 spike variants SARS-like coronavirus SARS-like coronaviruses sequence single nucleotide Spike protein Spike proteins susceptibility susceptibility to infection target cell target cells the cell the spike protein transgenic unique variant variants Viral viral spike virus viruses while zoonotic
[DOI] 10.1371/journal.ppat.1009715 PMC 바로가기 [Article Type] Research Article

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants

SARS-CoV-2 변이체에 의한 감염을 예방하기 위한 비강내 유전자 요법

Research Article

Published on 2021-07-152022-09-10
Journal: PLoS Pathogens [Category] SARS, 변종,

[키워드] ACE2 administration affinity airway angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animals Antiviral approach bind binding caused Cell combating coronavirus Coronaviruses countermeasure CoV COVID-19 COVID-19 pandemic CoVs demonstrated effective Efficacy evade expression Gene therapy human ACE2 humans immune response improvement infecting Infection Intervention intranasal intranasally less long-lasting monoclonal antibodies monoclonal antibody mouse model nasal Nasal spray neutralize Pandemics pathogenicity pathologic consequence Patient Population pre-existing immunity Prevent Prophylaxis Protein proximal receptor reduce respond SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral secrete significantly Spread tested the patient therapeutic Transmissibility unlikely vaccination Vaccinations Vaccine Vaccines variant variants variants of SARS-CoV-2 Viral viral mutation Viral mutations viral particle Viral particles Viral vector virus Vulnerable populations zoonosis
[DOI] 10.1371/journal.ppat.1009544 PMC 바로가기 [Article Type] Research Article

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

코로나19 후보 벡터백신 MVA-SARS-2-S의 전임상 접종에서 면역원성과 효능

423

Published on 2021-07-132022-09-10
Journal: Proceedings of the National Academy of Sciences of [Category] SARS, 비임상, 진단,

[키워드] acute respiratory syndrome Adenovirus Administered Antigen approved binding breath candidate vaccine cause CD8 cellular Characteristics children clinical evaluation clinical experience clinical trial component consequence coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccines disease Ebola virus disease economics Efficacy expresse expressing expression full-length SARS-CoV-2 growth Health heterologous prime-boost homologous Human human ACE2 Humoral immunity immunization immunocompromised individuals immunogenicity Infection infectious agent intramuscular investigated MERS-CoV mice Middle East Middle East respiratory syndrome Coronavirus modified vaccinia virus neutralized nonclinical testing pandemic coronavirus Phase I poxvirus produced Protective Protein reached resource respiratory respiratory syndrome coronavirus robust S protein Safe SARS-CoV-2 SARS-COV-2 infection serum antibodies serum antibody Severe acute respiratory syndrome Significance smallpox vaccine stability T cell T cells vaccination Vaccine vaccine vector vaccinia virus vector Virus Disease
[DOI] 10.1073/pnas.2026207118 PMC 바로가기 [Article Type] 423

A Fungal Defensin Targets the SARS−CoV−2 Spike Receptor−Binding Domain

Article

Published on 2021-07-122022-10-30
Journal: Journal of Fungi [Category] COVID-19,

Mathematical Model of SARS-Cov-2 Propagation Versus ACE2 Fits COVID-19 Lethality Across Age and Sex and Predicts That of SARS

Molecular Biosciences

Published on 2021-07-122022-10-31
Journal: Frontiers in Molecular Biosciences [Category] COVID-19,

The molecular basis for SARS-CoV-2 binding to dog ACE2

Article

Published on 2021-07-072022-10-04
Journal: Nature Communications [Category] SARS, 변종,

ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions

Research Article

Published on 2021-07-022022-10-29
Journal: PLoS Pathogens [Category] COVID-19, SARS,

[키워드] ACE2 analyses Analysis can be used Cell cell line COVID-19 COVID-19 patients COVID-19 research driving explain Express H353K hACE2 histological human ACE2 identify IFNAR in vitro in vivo infect infect cells Infection inflammatory disease Inflammatory response Inflammatory responses Interaction interferon response interferon signaling involved key amino acid lung lung epithelium mACE2 mice Mutagenesis no significant effect receptor Replication required rescued SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication SARS-CoV-2 research substitutions Support tissue repair transcriptomic profile transduction type I utility Vaccine Vaccines virus virus replication was used were used
[DOI] 10.1371/journal.ppat.1009723 PMC 바로가기 [Article Type] Research Article

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

CVnCoV 및 CV2CoV는 조상 B BavPat1 및 신흥 B.1.351 SARS-CoV-2로부터 인간 ACE2 형질전환 마우스를 보호합니다

Article

Published on 2021-06-302022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 진단, 치료기술,

[키워드] antibody Antibody titers B.1.351 B.1.351 variant BavPat1 Brain caused clinical development Complete controls CVnCoV detectable develop disease Efficacy elevated formalin groups hACE2 host immunity human ACE2 immunized K18-hACE2 lung mice Mortality mRNA mRNA vaccine mRNA vaccines mutant Mutation neutralization titer neutralization titers Neutralizing antibody titer PROTECT raise reduced SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant SARS-CoV-2 variants significantly Spike protein swabs the spike protein transgenic mice Transgenic mouse Vaccine vaccine efficacy Vaccines variants variants of concern Viral viral strain VoC was tested were used
[DOI] 10.1038/s41467-021-24339-7 PMC 바로가기 [Article Type] Article

AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2

530

Published on 2021-06-292022-10-29
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, SARS,